1-Bicyclo<2.2.1>heptylacetic Acid | 15019-83-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 1-Bicyclo<2.2.1>heptylacetic Acid
• 英文别名: 2-Norbornylacetic acid；2-(1-bicyclo[2.2.1]heptanyl)acetic acid
• CAS: 15019-83-7
• 化学式: C₉H₁₄O₂
• 分子量: 154.209
• InChiKey: NINSZYGJYPCNRP-UHFFFAOYSA-N

物化性质

• 沸点：
  271.7±8.0 °C(Predicted)
• 密度：
  1.166±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-肼基喹啉 、 1-Bicyclo<2.2.1>heptylacetic Acid 以to provide 8.8 mg (6%) of the title compound as a white solid的产率得到2-methyl-N'-quinolin-5-ylbicyclo[3.1.1]heptane-6-carbohydrazide
  参考文献：
  名称：

  Acylhydrazine P2X7 antagonists and uses thereof

  摘要：

  本发明揭示了一种式（I）的化合物或其药学上可接受的盐或前药，其中D，A，m，n，Rx和Ry在说明中定义。本发明还涉及式（I）化合物的药物组合物，其用于治疗选择自慢性炎性疼痛、神经病理性疼痛、炎症、神经退行性疾病、抑郁症和促进神经再生的疾病。本发明还涉及一种使用式（II）化合物、其药学上可接受的盐、酯、酰胺或前药治疗哺乳动物的疼痛、神经病理性疼痛、炎症、慢性炎性疼痛、神经退行性疾病、抑郁症和促进神经再生的方法，其中R3和R4在说明中定义。

  公开号：

  US20060276505A1
• 作为产物：
  描述：

  Lithium, (bicyclo[2.2.1]hept-1-ylmethyl)- 、 alkaline earth salt of/the/ methylsulfuric acid 以 乙醚 、 正戊烷 为溶剂， 以55%的产率得到1-Bicyclo<2.2.1>heptylacetic Acid
  参考文献：
  名称：

  Preparation of 1-substituted bicyclo[2.2.1]heptanes by anionic cyclization of a 5-hexen-1-yllithium

  摘要：

  DOI：

  10.1021/jo00311a028

文献信息

• Novel pyridine derivative and pyrimidine derivative
  申请人：Matsushima Tomohiro

  公开号：US20050277652A1

  公开（公告）日：2005-12-15

  A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R 1 represents C 1-6 alkyl or the like; R 2 and R 3 represent hydrogen; R 4 , R 5 , R 6 , and R 7 may be the same or different and each represents hydrogen, halogen, C 1-6 alkyl or the like; R 8 represents hydrogen or the like; R 9 represents C 1-6 alkyl or the like; V 1 represents oxygen or the like; V 2 represents oxygen or sulfur; W represents —NH— or the like; X represents —CH═, nitrogen or the like; and Y represents oxygen or the like.]

  以下化合物的分子式，其盐或前述水合物具有出色的肝细胞生长因子受体（HGFR）抑制活性，并表现出抗肿瘤活性、抑制血管生成活性和抑制癌转移活性。 [R 1 代表C 1-6 烷基或类似物；R 2 和R 3 代表氢；R 4 ，R 5 ，R 6 和R 7 可以相同也可以不同，每个代表氢、卤素、C 1-6 烷基或类似物；R 8 代表氢或类似物；R 9 代表C 1-6 烷基或类似物；V 1 代表氧或类似物；V 2 代表氧或硫；W代表—NH—或类似物；X代表—CH═、氮或类似物；Y代表氧或类似物。]
• DERMATOLOGICAL COMPOSITIONS AND METHODS
  申请人：——

  公开号：US20020141952A1

  公开（公告）日：2002-10-03

  Disclosed are methods and compositions for regulating the melanin content of mammalian melanocytes; regulating pigmentation in mammalian skin, hair, wool or fur; treating or preventing various skin and proliferative disorders; by administration of various compounds, including alcohols, diols and/or triols and their analogues.

  公开了用于调节哺乳动物黑素细胞的黑色素含量的方法及组合物；通过施用包括醇、二醇和/或三醇及其类似物在内的各种化合物，来调节哺乳动物皮肤、毛发、羊毛或毛皮的色素沉着；以及治疗或预防各种皮肤和增殖性障碍。
• Somatostatin-Dopamine Chimeric Analogs
  申请人：DONG Zheng Xin

  公开号：US20150290330A1

  公开（公告）日：2015-10-15

  The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.

  本发明涉及新型生长抑素-多巴胺嵌合类似物及其用于抑制、预防和/或治疗肿瘤、神经内分泌肿瘤、库欣病/综合征和其他疾病的治疗用途。
• [EN] ALIPHATIC PROLINAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE PROLINAMIDE ALIPHATIQUE
  申请人：INCEPTION 4 INC

  公开号：WO2017222917A1

  公开（公告）日：2017-12-28

  This invention is directed to novel aliphatic prolinamide derivatives of Formula I, and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRAl. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRAl. The compounds of the invention are also useful for inhibiting HTRAl protease activity in an eye or locus of an arthritis or related condition.

  这项发明涉及一种新型的脂肪族脯氨酰胺衍生物，其化学式为I，并且包括药学上可接受的盐、溶剂化合物、盐的溶剂化合物和其前药，用于预防（例如，延缓或减少发展风险）和治疗（例如，控制、缓解或减缓进展）与眼睛相关的年龄相关性黄斑变性（AMD）及相关眼部疾病。这些疾病包括干性AMD、湿性AMD、地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变、多发性脉络膜血管病变以及视网膜或光感受器细胞的退化。本公开的发明还涉及预防、减缓进展和治疗干性AMD、湿性AMD和地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变、多发性脉络膜血管病变以及视网膜或光感受器细胞的方法，包括：给予所述发明化合物的治疗有效量。本发明的化合物是HTRAl的抑制剂。因此，本发明的化合物在预防和治疗一系列（全部或部分）由HTRAl介导的疾病中具有用途。本发明的化合物还可用于抑制眼部或关节炎或相关疾病部位的HTRAl蛋白酶活性。
• [EN] PYRIMIDINYL-PYRIDYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1-RELATED DISEASES AND DISORDERS<br/>[FR] COMPOSÉS PYRIMIDINYL-PYRIDYLOXY-NAPHTYLE ET PROCÉDÉS DE TRAITEMENT DE MALADIES ET DE TROUBLES LIÉS À IRE1
  申请人：GENENTECH INC

  公开号：WO2018166528A1

  公开（公告）日：2018-09-20

  Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula (I) or (I') structure : or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula (I) or (I') compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本文描述了具有肌醇需要酶1（IRE1）调节活性或功能的嘧啶基-吡啶氧基-萘基化合物，其具有公式（I）或（I'）结构：或其立体异构体，互变异构体或药学上可接受的盐，并具有所述的取代基和结构特征。还描述了包括公式（I）或（I'）化合物的制药组合物和药物，以及使用这种IRE1调节剂的方法，单独或与其他治疗剂联合治疗介导或依赖于雌激素受体的疾病或病况。